DefiniGEN will be attending SLAS 2024 in Boston, Feb 3-7

This year's theme for SLAS is "innovation at every turn!" - a subject that resonates deeply with DefiniGEN. We will be talking about our latest toxicology data where we demonstrate that our innovative, iPSC derived hepatocytes (Opti-Heps) can predict toxicology comparable, if not better, than carcinoma cell lines and, due to their greater functionality (e.g., albumin/ urea secretion, bile acid

transporters, etc), they have great potential for efficacy screening and ADME assays.

Contact us if you would like to arrange a meeting with DefiniGEN at SLAS.